Appointment of Chief Financial Officer

Sphere Medical Holding plc

Appointment of Chief Financial Officer

Cambridge, UK, 16 July 2015: Sphere Medical Holding plc (AIM: SPHR.L), ("Sphere Medical" or the "Company") a leading provider of innovative monitoring and diagnostic devices for the critical care setting, is pleased to announce the appointment of Richard Wright as Chief Financial Officer. Richard will join the Company and the Board with effect from 10 August 2015.

From 2007 to 2015, Richard was Finance Director of Alliance Pharma plc, the UK based AIM-listed speciality pharmaceutical company. He is a Chartered Accountant with more than 20 years of experience in financial roles across a variety of sectors. Richard read Mathematics at Cambridge University and qualified as an accountant with Ernst & Young LLP.

Commenting on the appointment, Dr. Wolfgang Rencken, Chief Executive Officer of Sphere, said: "We are delighted to have attracted someone of Richard's calibre. His track record of managing Alliance Pharma through a strong commercial growth phase, as well as his extensive experience in negotiating and implementing numerous commercial deals, will strengthen our executive management team as we continue with the commercialisation of Proxima."

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Richard David Wright, aged 48 years, has been a director of the following companies during the five years preceding the date of this announcement:

Current directorships:

None

Past directorships:

Alliance Pharma plc

Alliance Pharmaceuticals Ltd

Alliance Pharmaceuticals GmbH (Germany)

Alliance Pharmaceuticals SAS (France)

Alliance Health Ltd

Dermapharm Ltd

Opus Group Holdings Ltd

Opus Healthcare Ltd (UK)

Opus Healthcare Ltd (Ireland)

Macuvision Europe Ltd

Options granted:

Pursuant to the Company's EMI Share Option Scheme, on 16 July 2015 1,340,000 share options were granted to Richard Wright at an exercise price of 17.75 pence each which are exercisable over ordinary shares of 1 pence each in the share capital of the Company. The exercise price of 17.75 pence equates to the closing mid market share price on 15 July 2015.

These share options are subject to vesting conditions and a minimum holding period of five years from grant. The issue of these share options has been approved by the Company's Remuneration Committee.

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

For further information, please contact:

Notes for Editors

About Sphere Medical (AIM: SPHR.L)

Sphere Medical is a medical device company developing and commercialising a range of innovative monitoring and diagnostic devices designed to significantly improve patient care.

Sphere Medical's vision is to become a leading solution provider to the critical care market offering innovative, near real time, point of care diagnostic and monitoring products to enable closer control of therapeutic response and improve patient outcomes and reduce the overall cost of care.

The Company's strategy is focused on developing the Proxima (CE-marked device) platform for measuring blood gases, electrolytes and metabolites. The Company is already marketing its Proxima product directly to the critical care market, which includes the ICU and OR, with a dedicated field sales force in the UK, Germany, the Netherlands and Belgium. The Company also proposes to work with partners for the worldwide distribution of Proxima.

Proxima delivers near real time analysis of blood gases and electrolytes metabolites, at the patient's bedside. Proxima can be used on patients across a wide therapeutic range, enabling faster clinical decision making and improved patient outcomes, whilst potentially reducing costs for healthcare payers.

Sphere Medical entered into a collaboration agreement with Ortho-Clinical Diagnostics (now part of Carlyle Group) in 2013 for the development of Proxima and enhancement of Sphere Medical's operational and production capabilities.

For further information, please visit www.spheremedical.com